AVBCC 2013 3rd Annual Conference Abstracts
Low Incidence of Treatment-Induced Peripheral Neuropathy (PN) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Treated with Single-Agent Carfilzomib
Thomas Martin, Ravi Vij, Ashraf Z. Badros, Leanne McCulloch, Sundar Jagannath University of California-San Francisco, San Francisco, CA, USA; Washington University School of Medicine, St. Louis, MO, USA; Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA; Onyx Pharmaceuticals, South San Francis
Background: Treatment of patients with RRMM can be challenging because of debilitating PN caused by the disease itself or by MM treatments. Neuropathy at diagnosis is prevalent (20–54%, depending on evaluation type [Richardson PA, et al. J Clin Oncol. 2009]) and can commonly be exacerbated by MM treatments (eg, bortezomib- or thalidomide-induced PN; BIPN or TIPN). PN reduces quality of life and leads to increased PN-related healthcare expenditures (eg, diagnostic testing and pharmaceutical and non-pharmaceutical interventions [Snowdon JA, et al.
Effects of 5-Hydroxytryptamine-3 Receptor Antagonists (5-HT3 RAs) in Lung Cancer Patients with Multiple Risk Factors
Background: Chemotherapy induced nausea and vomiting (CINV) is a major adverse effect of cancer treatment. The 5-HT3 RAs are indicated for the prevention of CINV. Certain factors such as age <50 years, female gender, prior CINV, anxiety, no or minimal alcohol use, history of motion sickness, and emetogenicity of chemotherapy have been associated with increasing the likelihood of a CINV event. We examined the impact of palonosetron vs. other 5-HT3 RAs on incidence of delayed CINV at cycle 1 based on presence of certain risk factors in patients with Lung Cancer.
Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving 5-HT3-RA Therapy throughout Chemotherapy Cycles
Objective: Current guidelines support the use of 5-HT3-RAs for chemotherapy-induced nausea and vomiting (CINV). Controlling CINV upon chemotherapy initiation is important as the likelihood of CINV in future chemotherapy cycles increases if a patient experiences CINV in the first/previous chemotherapy cycle. The purpose of this study was to evaluate the overall rate of CINV, and compare the odds of CINV per chemotherapy cycle in patients with lung cancer receiving the same 5-HT3-RA throughout chemotherapy cycles.
An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)
Background: Racial disparities in clinical outcomes between Caucasian and African American (AA) MBC patients have been identified. Some of these disparities may be attributed to differences in toxicities and access to supportive care interventions. In this study, treatment toxicities and use of supportive care were compared between Caucasian and AA MBC patients treated in 15 community oncology practices across the United States.
Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
Introduction: EM is a microtubule inhibitor shown to improve overall survival in metastatic breast cancer patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. There are side effects of EM, including neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. While some physicians discontinue treatment due to side effects, others manage side effects using dose delays/skipped doses and/or dose modifications.
Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia
Gluck S, Yardley D, Belk K, Craver C, Cox D, Faria C, University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ
Background: Eribulin mesylate (EM) is a microtubule inhibitor shown to improve survival in patients with metastatic breast cancer (MBC) who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. A common grade 3/4 toxicity of EM is neutropenia which may result in dose adjustments and dose delays. To minimze neutropenic complications, granulocyte colony-stimulating factor (GCSF or GMCSF) may be utilized, as well as dose modifications or treatment discontinuation.
Joanne Growney, MA, RN, ANP-BC, OCN, Rebecca Martin, BSN, RN, OCN, Phyllis McKiernan, RN, MSN, APN-BC, Joan Collela, RN, DNP, APN-BC, NP-C, Claudia Douglas, RN, MA, CNN, APN-C
Background: Chemotherapy and radiation therapy, the mainstays of current cancer treatment, often result in devastating side effects involving the oral cavity. Mucositis, an inflammatory and/or ulcerative lesion of the oral and/or gastrointestinal tract is a common therapy-related toxicity. Mucositis significantly impacts patients’ overall physical and functional well-being, as well as quality of life.
Background: Breast Care at IU Health North Hospital is a multidisciplinary clinic comprised of breast surgeons, medical and radiation oncologists, plastic surgeons and geneticists. It has consistently achieved excellent patient satisfaction scores; however, one area needing improvement was in office wait time.
Background: The introduction of tyrosine kinase inhibitors (TKIs) into clinical practice resulted in a very dramatic prolongation of survival for most, but not all patients with chronic myeloid leukemia (CML) in chronic phase. If properly managed, and if adherence is greater than 80%, the 10-year survival rate reaches 85% for patients treated with the 1st-generation (Gen) TKI, imatinib (Gleevec). Currently, there are five TKIs available for CML. Clinicians must weigh the relative advantages and toxicities of each when selecting a course of treatment.
Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib
Kevin B. Knopf, MD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, MS, Patrick Lefebvre, MA, Liviu Niculescu, MD, Abbie Ba-Mancini, MBA, Esprit Ma, MPH, Mei Sheng Duh, MPH, ScD
Background: In an era of multiple effective treatment options for relapsed/refractory multiple myeloma (MM), a recent meta-analysis has shown that retreatment with bortezomib continues to be an effective option in previously treated patients who relapsed. As economic pressures rise in oncology, it is important to evaluate the cost-effectiveness of newer therapies relative to standards of care. Carfilzomib was recently approved by the US Food and Drug Administration for the treatment of relapsed/refractory MM.
Page 1 of 3
Results 1 - 10 of 26
Results 1 - 10 of 26